Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00953277 · ClinicalTrials.gov registry record · Phase 4

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

A Phase 4 study of Prostate Cancer and Peripheral Nerve Injury, sponsored by Axogen Corporation.

Completed
Registry status
Phase 4
Development phase
12
Enrollment target
1
Study location

NCT00953277: Completed Phase 4 study of Prostate Cancer and Peripheral Nerve Injury, sponsored by Axogen Corporation.

NCT00953277 is a Phase 4 study of Prostate Cancer and Peripheral Nerve Injury that has completed, run by Axogen Corporation. The registered enrollment target is 12 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00953277, a Phase 4 study of Prostate Cancer and Peripheral Nerve Injury, has completed, sponsored by Axogen Corporation.

COMPLETED
Registry status
Phase 4
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if it is technically feasable to repair nerves that are injured as part of a planned surgical removal of the prostate and the surrounding tissue in subjects with prostate cancer. The study will also examine the long term outcomes on erectile function, continence and overall quality of life in the enrolled subjects.

Interventions

  • OTHER Processed Human Nerve Tissue Scaffold

Study Locations (1)

Tennessee

  • Vanderbilt University - Nashville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2009-08
Est. Completion 2015-04
Phase Phase 4
Axogen Corporation

10 total trials

What the finished NCT00953277 record still lists

NCT00953277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower).

The record links to 5 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Processed Human Nerve Tissue Scaffold is the first listed.

NCT00953277 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT00953277 about?

NCT00953277 is a clinical study titled "Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer". The purpose of this study is to determine if it is technically feasable to repair nerves that are injured as part of a planned surgical removal of the prostate and the surrounding tissue in subjects with prostate cancer. The study will also examine the long term outcomes on erectile function, contin...

What is the current status of trial NCT00953277?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2009-08. Estimated completion is 2015-04.

What conditions does trial NCT00953277 study?

This clinical trial studies the following conditions: Prostate Cancer, Peripheral Nerve Injury, Radical Prostatectomy, Nerve Reconstruction, Cavernous Nerve Injury.

What interventions are being tested in trial NCT00953277?

The interventions under investigation include: Processed Human Nerve Tissue Scaffold (OTHER).

Who is sponsoring clinical trial NCT00953277?

This trial is sponsored by Axogen Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00953277 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00953277's enrollment target sits among peer trials

12 703rd of 735 higher than 23 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00953277, the US trial registry maintained by the National Library of Medicine. NCT00953277 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.